secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001193125-24-026692
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana reports SC291 ARDENT interim data with responses and immune evasion; cash $205.4M
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities as of Jan 2, 2024: approximately $205.4 million.
- ARDENT interim: 4 evaluable patients; 3 partial responses including ongoing complete responses; no DLTs, GVHD, or CRS/ICANS.
- HIP-edited CAR T cells evaded innate and adaptive immune responses in all 4 evaluable patients; non-HIP cells were recognized.
- IND cleared for GLEAM (lupus/vasculitis) and VIVID (CD22 CAR T) trials; data expected in 2024.
- Preclinical: HIP primary islets in diabetic NHP achieved insulin independence for 6 months without immunosuppression; IST of UP421 authorized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312524026692/0001193125-24-026692-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312524026692/d180813d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-026692

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer